@Article{,
AUTHOR = {Judd W. Moul, Grannum R. Sant},
TITLE = {How I Use It: The Exosome Diagnostics (EPI)  prostate cancer biomarker utility in urology  and primary care},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {29},
YEAR = {2022},
NUMBER = {4},
PAGES = {11224--11230},
URL = {http://www.techscience.com/CJU/v29n4/59870},
ISSN = {1488-5581},
ABSTRACT = {Prostate-specific antigen (PSA) screening remains the mainstay for early detection of prostate cancer.  Although PSA is a nonspecific prostate cancer biomarker, its specificity for high grade prostate cancer can be enhanced by pre-biopsy liquid biomarkers including the Exosome Dx Prostate IntelliScore (EPI) test. <br/>
EPI is a stand-alone urine genomic test that measures 3 exosome-derived gene expression signatures without the need for digital rectal examination (DRE) or inclusion of standard of care parameters in the test algorithm.  EPI has broad clinical utility as a risk stratification tool for clinically significant high grade prostate cancer in men considering diagnostic prostate biopsy (MRI-targeted and systematic biopsy). <br/>
During the COVID-19 pandemic, the EPI At-Home Collection Kit was introduced and quickly became an important component of tele-urology.  The EPI test has emerged as a prioritization tool for primary care referral to urologists and for prostate biopsy scheduling. <br/>
EPI provides an objective and actionable genomic risk assessment tool for high grade prostate cancer and is a critical part of the informed decision-making regarding biopsy (targeted, systematic or both) in both urology and primary care practices. },
DOI = {}
}